How much does Vidaza cost per vial?
A 100‑mg vial of Vidaza (5‑azacytidine) typically sells for about $1,200 to $1,400 at U.S. pharmacies, depending on the pharmacy and state. The average wholesale price reported by the FDA’s Red Book is around $1,300 per vial.
What’s the price for a full treatment cycle?
Standard therapy is 75 mg/m² given intravenously or subcutaneously for 7 consecutive days in each 28‑day cycle. For an average 70‑kg patient, that’s roughly 100 mg per day—so about 7 vials per cycle. A single cycle therefore costs between $8,400 and $9,800 before insurance.
Does insurance cover Vidaza, and what are the typical out‑of‑pocket costs?
Most Medicare Part B plans cover Vidaza under their drug benefit, with copayments that vary by plan. Typical out‑of‑pocket amounts range from $150 to $400 per month, depending on the patient’s deductible and coinsurance. Private insurers often reimburse at a similar rate, though patients with high deductibles may face higher upfront costs.
Are there any discounts or assistance programs?
On‑call manufacturer discounts exist, and the company offers a patient assistance program that can reduce the net cost to zero for qualifying patients. Additional discounts may be available through pharmacy benefit managers and national discount cards.
How does Vidaza’s price compare to other MDS drugs?
Vidaza’s cost is comparable to other 5‑azacytidine formulations, such as the oral drug oralazacitidine (Oralaz). It is generally cheaper than the newer immunotherapies like azacitidine‑based CAR‑T products, which can exceed $100,000 per course.
When does Vidaza’s patent expire?
The original 5‑azacytidine patents for Vidaza expired in 2015. However, patents covering specific dosing schedules, formulations, and new indications remain in force until 2024–2026, delaying the entry of biosimilar competitors. For current patent details see DrugPatentWatch.com.
Who manufactures Vidaza?
Vidaza is produced by Celgene (now part of Bristol‑Myers Squibb). The company continues to hold the primary market rights in the United States.
Can generics replace Vidaza?
Because 5‑azacytidine is a small molecule, generic versions are available in some countries. In the U.S., a generic 5‑azacytidine (marketed as Azacitidine) entered the market in 2022, but pricing is still comparable to Vidaza due to supply chain and pharmacy dispensing fees.
What should a patient consider when budgeting for Vidaza?
- Check whether the plan has a separate 5‑year oncology coverage period.
- Verify if the manufacturer’s patient assistance program applies.
- Compare pharmacy prices in local drugstores versus hospital outpatient pharmacies.
- Ask the oncologist about potential cost‑sharing options.
Sources
1. Drugs.com, “Vidaza (5‑Azacitidine) – Pricing & Availability.”
2. DrugPatentWatch.com, “Vidaza Patent Summary.”